A retrospective study on the efficacy of Ninjin'yoeito on fatigue in patients with interstitial pneumonia
- PMID: 34298370
- DOI: 10.1016/j.npep.2021.102178
A retrospective study on the efficacy of Ninjin'yoeito on fatigue in patients with interstitial pneumonia
Abstract
Introduction: Fatigue, caused by dyspnea associated with progression of interstitial pneumonia (IP), can negatively affect patients' quality of life (QOL). Ninjin'yoeito (NYT), a Chinese herbal medicine, is prescribed for general symptoms of fatigue and for fatigue associated with various respiratory diseases. However, there is a lack of integrated research on the effects of NYT in patients with IP. Therefore, we retrospectively investigated the efficacy of NYT in patients with IP and fatigue.
Materials and methods: From the IP patients who had taken NYT, 19 who met the following inclusion criteria were included: (1) age of ≥20 years, (2) fatigue, and (3) history of NYT administration. The primary endpoint was fatigue, which was assessed using the Chalder Fatigue Scale (CFS). The secondary endpoints were loss of appetite and dyspnea, which were evaluated using the Simplified Nutritional Appetite Questionnaire (SNAQ) and modified Medical Research Council (mMRC) scores, respectively. All items were measured before and after 12 weeks of NYT administration.
Results: In the enrolled 19 patients (male, 12; female, 7; mean age, 65.8 ± 12.7 years), the underlying diseases were idiopathic pulmonary fibrosis (n = 8), idiopathic pleuroparenchymal fibroelastosis (n = 5), connective tissue disease-related interstitial pneumonia (n = 2), chronic hypersensitivity pneumonitis (n = 3), and nonspecific interstitial pneumonia (n = 1). The CFS score decreased from 17.1 ± 6.8 before administration to 13.4 ± 5.7 after administration of NYT (p = 0.0389). The SNAQ score did not change markedly. The median mMRC score decreased from 3 to 2, however, the difference was not significant.
Conclusion: Many subtypes of IP are progressive, and a cure cannot be expected in cases of irreversible lung fibrosis. Therefore, a multifaceted approach to improve and maintain the QOL is needed in addition to the standard of care. This study showed that NYT can improve fatigue and help maintain the QOL in IP patients.
Keywords: Fatigue; Interstitial pneumonia; KL-6; Ninjin'yoeito; Quality of life.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Similar articles
-
Usefulness of Ninjin'yoeito for Chronic Obstructive Pulmonary Disease Patients with Frailty.J Altern Complement Med. 2020 Aug;26(8):750-757. doi: 10.1089/acm.2020.0083. Epub 2020 Jun 17. J Altern Complement Med. 2020. PMID: 32551796 Clinical Trial.
-
Safety and efficacy of Ninjin'yoeito along with iron supplementation therapy for preoperative anemia, fatigue, and anxiety in patients with gynecological disease: an open-label, single-center, randomized phase-II trial.BMC Womens Health. 2022 Jun 14;22(1):229. doi: 10.1186/s12905-022-01824-9. BMC Womens Health. 2022. PMID: 35701778 Free PMC article. Clinical Trial.
-
Efficacy of Ninjin'yoeito in treating severe coronavirus disease 2019 in patients in an intensive care unit.Neuropeptides. 2021 Dec;90:102201. doi: 10.1016/j.npep.2021.102201. Epub 2021 Oct 1. Neuropeptides. 2021. PMID: 34753072 Free PMC article.
-
Ninjin'yoeito, a herbal medicine, enhances glucose tolerance in mice.Neuropeptides. 2021 Aug;88:102150. doi: 10.1016/j.npep.2021.102150. Epub 2021 Apr 16. Neuropeptides. 2021. PMID: 33895618 Review.
-
Perspectives on the Use of Ninjin'yoeito in Modern Medicine: A Review of Randomized Controlled Trials.Evid Based Complement Alternat Med. 2019 Sep 2;2019:9590260. doi: 10.1155/2019/9590260. eCollection 2019. Evid Based Complement Alternat Med. 2019. PMID: 31565066 Free PMC article. Review.
Cited by
-
A Herbal Prescription of Insamyangyeongtang as a Therapeutic Agent for Frailty in Elderly: A Narrative Review.Nutrients. 2024 Mar 1;16(5):721. doi: 10.3390/nu16050721. Nutrients. 2024. PMID: 38474849 Free PMC article. Review.
-
Ninjin'yoeito improves respiratory symptoms after lung cancer surgery: a prospective randomized study.Surg Today. 2025 May;55(5):693-704. doi: 10.1007/s00595-024-02977-w. Epub 2024 Dec 24. Surg Today. 2025. PMID: 39718597 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous